Entries by oslocancer

Prestigious partnership for Vaccibody

Oslo Cancer Cluster member Vaccibody is entering into a clinical collaboration with the American biopharmaceutical company Nektar Therapeutics. The aim of the collaboration is to explore positive effects from the combination of Vaccibody’s personalized cancer vaccine VB10.NEO and Nektar Therapeutics cancer drug NKTR-214. Pre-clinical results of the combination are very positive and the collaboration will […]

American tech and Norwegian health data

Combining country scale population data with world class computer systems and algorithms will push the boundaries of precision medicine. This is a story about the unique American-Norwegian collaboration that combines the best health data with the most powerful computers in a pioneer project run by Cancer Registry of Norway and Lawrence Livermore National Laboratory. Data to screen […]

Norwegian life science on exhibition

The strong life science actors in Norway joined forces during the conference Nordic Life Science Days 2018. Oslo Cancer Cluster aims to enhance the visibility of oncology innovation made in Norway by being a significant partner for international clusters, global biopharma companies and academic centres. We used the conference Nordic Life Science Days 2018 in Stockholm this […]

The next wave in cancer immunotherapy

What is driving the next wave of innovation in cancer immunotherapy? This was the question the experts tried to answer in the oncology session of the conference Nordic Life Science Days in Stockholm 12 September. International experts from pharma, biotech, academia and the investment community discussed how different approaches to innovative cancer treatments could address […]

Ultimovacs acquires Immuneed

The Norwegian biotech company Ultimovacs acquires the immunotherapy technology business of the Swedish company Immuneed AB.  The complementary technologies of the two companies provide a unique platform for development of novel vaccine solutions for treatment and possibly prevention of cancer. The acquired business has been named Ultimovacs AB and is now a fully-owned Swedish subsidiary […]

PCI Biotech with new research collaboration

PCI Biotech is initiating a scientific collaboration with Bavarian Nordic to boost their cancer treatment technology. Oslo Cancer Cluster member PCI Biotech has announced that it is initiating a preclinical research collaboration with Bavarian Nordic, a clinical stage biopharmaceutical corporation focused on developing state-of-the-art cancer immunotherapies and vaccines for infectious diseases. The two collaborators will […]

Get to know our new chairman

CEO of Ultimovacs Øyvind Kongstun Arnesen is the new chairman of Oslo Cancer Cluster. Get to know the guy! An Oslo born family man who likes the outdoors, and took the jump from hospital work to entrepreneurship by the way of the health industry.  Remarkably, before all this he dazzled the audience at the National […]

In need of start-up funding?

Are you and your cluster company in need of early stage funding? Apply for Innovasjonsrammen by the 10th of September and compete for important start-up money. Early financing for establishing companies is often limited, but can be absolutely crucial to get important projects off the ground. Therefore, Innovation Norway has created the special funding program […]

Can Norway compete internationally on health?

Can Norway take a leading international position within the health industry? This was the main question for one of our discussions at Arendalsuka last week. A report released in April this year shows a Norwegian health industry on the rise. However internationally, Norway is still comparatively small even compared to our Nordic neighbors. SEE VIDEO FROM […]